MediWound Reports US Commercial Availability Of NexoBrid For Treatment Of Severe Thermal Burns In Adults
Portfolio Pulse from Benzinga Newsdesk
MediWound has announced the US commercial availability of NexoBrid, a treatment for severe thermal burns in adults.
September 21, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediWound's NexoBrid is now commercially available in the US, potentially increasing the company's market share and revenues.
The commercial availability of NexoBrid in the US represents a significant milestone for MediWound. This could potentially increase the company's market share in the burn treatment sector and boost its revenues. Given the size of the US market, this development is highly relevant and important for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100